<DOC>
	<DOCNO>NCT00868985</DOCNO>
	<brief_summary>The study evaluate influence three different dos PEG 3350 without electrolyte electrolyte balance patient volunteer confirm chronic constipation .</brief_summary>
	<brief_title>Effects Oral PEG 3350 Electrolyte Balance</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>1 . The subject write informed consent must obtain prior inclusion . 2 . Male female patient 18 70 year age confirm chronic constipation runin period ; define patient record diary less 3 bowel motions/week plus one following symptom : Straining least 25 % defecation Lumpy hard stool least 25 % defecation Sense incomplete evacuation least 25 % defecation Sensation anorectal blockage least 25 % defecation Manula manoeuvre facilitate least 25 % defecation 3 . Willing able follow entire procedure comply study instruction . 4 . For subgroup patient volunteer take ACEinhibitors ( 36 subject ) : A history hypertension , blood pressure control acceptable level stable regimen ACEinhibitors . 1 . Participation clinical research study involve investigational drug dosage form within previous 3 month . 2 . Subjects previously enrol study . 3 . Subjects currently history abuse alcohol , nonmedical drug , medicinal drug substance abuse eg solvent . 4 . Major surgery within last 12 month . 5 . Malignant tumor within last 5 year . 6 . Uncontrolled blood pressure terminal cardiac , liver and/or kidney disease . 7 . Clinical relevant acute gastrointestinal tract disease , include evidence intestinal perforation obstruction , paralytic ileus , toxic megacolon , severe inflammatory condition . 8 . Acute urinary tract condition , include cystitis . 9 . Patients diagnosis evidence follow disease : Hypothyroidism , diabetes mellitus , porphyria , pituitary gland insufficiency , pheochromocytoma , glucagonoma , neurological disease ( eg Hirschprung disease , neurofibromatosis , Chagas disease , stroke , autonomous neuropathy , intestinal pseudoobstruction , Multiple sclerosis , medullar injury , Parkinson disease , ShyDrager syndrome ) , collagenosis , vasculitis , myopathy ( e.g . sclerodermatitis , amyloidosis , dermatomyositis ) , intoxication heavy metal ( e.g . Pb , As , Hg ) 10 . Concomitant medication : 1 . Use oral purgatives/laxatives prokinetics within last 14 day prior dose . 2 . Use opioids , anticholinergic , tricyclic antidepressant , MAOIs , Fe preparation , within 4 week prior dose . 3 . Use Caantagonists , Betablockers diuretic within last 4 week prior dose . 4. medication opinion Investigator could interfere principal function GI tract . 11 . Subject unable provide write consent . 12 . Failure satisfy Investigator fitness participate reason , include suspect noncompliance . 13 . Women childbearing potential , use willing use medically reliable method contraception entire study duration , unless surgically sterilised/hysterectomised criterion consider sufficiently reliable Investigator individual case . 14 . Patients electrolytes disturbance clinical sign dehydration . 15 . Positive test screen HIV hepatitis . 16 . Any clinically significant abnormal test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>